Impax Asset Management Group plc Boosts Stake in Zoetis Inc. $ZTS

Impax Asset Management Group plc increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 362.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,176,996 shares of the company’s stock after buying an additional 922,589 shares during the quarter. Impax Asset Management Group plc’s holdings in Zoetis were worth $182,705,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. purchased a new position in shares of Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC acquired a new stake in Zoetis during the 1st quarter worth $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter worth $29,000. REAP Financial Group LLC grew its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC increased its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $121.30 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock’s 50 day moving average is $142.21 and its two-hundred day moving average is $151.94. Zoetis Inc. has a twelve month low of $117.26 and a twelve month high of $181.85. The firm has a market capitalization of $53.45 billion, a PE ratio of 20.88, a P/E/G ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the firm earned $1.58 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s dividend payout ratio is 33.67%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ZTS shares. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Stifel Nicolaus set a $140.00 price objective on Zoetis in a research report on Tuesday, November 4th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, BTIG Research lowered their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $180.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.